SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Acasti Pharma Inc. (ACST) , forward earnings yield 6.83%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 14.7
- PEG Ratio 0.02 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 37/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ACST
Valuation Multiples
P/E (TTM)0.0
Forward P/E14.7
PEG Ratio0.02
Forward PEG0.02
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.79
Forward EPS (Est.)$0.23
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield6.83%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-20.99 |
$27.79K |
$-4.66M |
-16773.4% |
| 2016 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2017 |
$-7.75 |
$0.00 |
$-16.94M |
- |
| 2018 |
$-6.46 |
$0.00 |
$-43.86M |
- |
| 2019 |
$-14.62 |
$0.00 |
$-25.76M |
- |
| 2020 |
$-7.96 |
$196K |
$-19.68M |
-10039.8% |
| 2021 |
$-1.60 |
$0.00 |
$-9.82M |
- |
| 2022 |
$-5.71 |
$0.00 |
$-42.43M |
- |
| 2023 |
$-1.35 |
$0.00 |
$-12.85M |
- |
| 2024 |
$-0.79 |
$0.00 |
$-12.77M |
- |
